Related by context. All words. (Click for frequent words.) 75 progesterone receptor PR 73 estrogen receptor progesterone receptor 73 progesterone receptor negative 73 estrogen receptor negative 72 ERalpha 71 estrogen receptor positive 70 CagA 70 K ras mutations 69 HER2 receptor 69 ERBB2 69 estrogen receptor 69 cytokeratin 69 breast carcinoma 68 TOP2A 68 Estrogen receptor 68 thyroglobulin 68 BRAF V#E mutation 68 p#HER# 68 poorer prognosis 68 BRAF mutation 68 AGTR1 68 HER2 expression 68 breast cancer subtypes 68 epithelial tumors 68 lymph node metastasis 68 CD#c 67 rheumatoid factor 67 HER2 negative 67 breast carcinomas 67 HER2/neu 67 histological subtype 67 TMPRSS2 ERG 67 FLT3 67 immunoreactivity 66 HER-2/neu 66 HER2 overexpression 66 KRAS mutations 66 ERa 66 estrogen receptor beta 66 EGFR mutation 66 carcinoembryonic antigen 66 hormone receptor positive 66 ABCB1 66 HER2 neu 66 HER2 positive cancers 66 TNFalpha 66 tumor histology 66 PCa 66 CTNNB1 66 prostate cancer CaP 66 TIMP 66 Clusterin 66 progesterone receptor 66 HBeAg 66 HBsAg 66 ovarian carcinoma 66 ERCC1 66 urothelial carcinoma 66 atypical hyperplasia 66 Akt activation 66 immunostaining 65 mucinous 65 pCR 65 lymphovascular invasion 65 Her2/neu 65 Ki# 65 mRNA expression 65 hormone receptor negative 65 pDCs 65 pancreatic adenocarcinoma 65 vimentin 65 cyclin E 65 operable breast cancer 65 mutated K ras 65 node metastases 65 urine cytology 65 lobular carcinoma 65 Hormone receptor 65 colorectal carcinoma 65 TIMP 1 65 hepatoma 65 ER alpha 65 cagA 65 KRAS mutation 65 EGFR protein 65 activin 64 microsatellite instability 64 progesterone receptors 64 EpCAM 64 inducible nitric oxide synthase 64 RASSF1A 64 K ras 64 GSTP1 64 HER2 ErbB2 64 immunohistochemical staining 64 lymph node metastases 64 prognostic indicator 64 HER2 + 64 rs# [001] 64 cTnT 64 prognostic significance 64 HNSCC 64 promoter methylation 64 thyroid peroxidase 64 ErbB2 positive 64 EGFR expression 64 NSCLC tumors 64 constitutively active 64 autoantibody 64 B7 H4 64 seminal vesicle invasion 64 progesterone receptor positive 64 axillary nodes 64 immunohistochemical analysis 64 PDGFR alpha 64 5alpha reductase 64 eNOS 64 lymph node involvement 64 distant metastases 64 estrogen receptor alpha 64 nodal metastasis 64 SLNB 64 hormone receptor status 64 prostate carcinoma 64 lymphocytosis 64 interleukin IL -6 64 peripheral blood mononuclear 64 uPAR 64 TNF α 64 prognostic factor 64 gene polymorphism 64 LHRH receptor positive 64 c MYC 64 gene polymorphisms 64 immunohistochemical 63 CYP #D# 63 prostate cancer PCa 63 HepG2 cells 63 adrenoceptor 63 distant metastasis 63 GSTT1 63 EGFRvIII 63 GFAP 63 HER2 amplification 63 WT1 63 CD4 + CD# 63 VEGFR1 63 colorectal carcinomas 63 renal carcinoma 63 multivariate analyzes 63 HER2 63 tumorigenicity 63 MAGE A3 63 axillary lymph nodes 63 p# activation 63 CIN2 + 63 gastric adenocarcinoma 63 Her2 63 Immunohistochemical staining 63 locoregional recurrence 63 isoprostane 63 CD# expression [001] 63 interferon IFN 63 clinicopathological features 63 GPNMB 63 cisplatin resistant 63 mutated KRAS 63 serum prostate 63 ZNF# 63 HPV# 63 multivariate Cox 63 F FDG PET 63 T#I [002] 63 rs# [002] 63 SPINK1 63 CYP#D# genotype 63 invasive ductal 63 Mutational 63 colorectal adenocarcinoma 63 MDA MB 63 troponin T 62 IL#B 62 CD# expression [002] 62 micrometastasis 62 Estrogen Receptor 62 gastric carcinoma 62 atypia 62 KRAS wild 62 ERK activation 62 pT3 62 serous ovarian cancer 62 microvessel density 62 estrogen receptors 62 BRCA1 mutation carriers 62 cell adhesion molecule 62 ASCUS 62 missense mutations 62 PTPN# 62 CC genotype 62 UGT#A# 62 homozygotes 62 FDG uptake 62 ADAM# 62 iNOS 62 IGFBP 62 contralateral breast 62 univariate 62 MTHFR 62 JAK2 V#F 62 Lymph node 62 HER2 receptors 62 sarcomatoid 62 estrogen progesterone 62 gene amplification 62 CD# CD# 62 Tie2 62 preoperative PSA 62 VEGF expression 62 IL 1ß 62 tumoral 62 thyrotropin 62 caveolin 1 62 IFN gamma 62 P cadherin 62 Angiotensin converting enzyme 62 monocytic 62 effector function 62 immunohistochemistry 62 tryptase 62 interferon γ 62 obstructive coronary artery 62 situ LCIS 62 prognostic biomarker 62 B7 H3 62 ß catenin 62 RQ PCR 62 NMIBC 62 NKG2D 62 RRM1 62 isoenzyme 62 factor receptor 62 syngeneic 62 p# mutation 62 P selectin 62 TGF ß1 62 folate receptor 62 IFN γ 62 lymphoproliferative disorders 62 myeloperoxidase 62 Rap1 62 castrate resistant 62 ERK1 2 62 APOE ε4 62 endometrial cancers 62 Leydig cell 62 Immunohistochemical analysis 62 adenocarcinomas 62 IGFBP 3 62 lactate dehydrogenase 62 advanced adenomas 62 TGF ß 62 CYP#A# [002] 62 renal cell carcinomas 62 hTERT 62 interleukin IL -# 62 cTnI 62 tumor subtypes 62 SNP rs# [001] 62 KRAS status 62 HLA DR4 62 clinicopathological 62 BRCA mutation carriers 62 biochemical relapse 61 endocrine therapy 61 aldehyde dehydrogenase 61 thymocytes 61 DQB1 * 61 epithelial ovarian cancer 61 BRAF V#E 61 antibody titer 61 MDR1 61 IL6 61 histologic subtypes 61 pT2 61 TRAIL induced apoptosis 61 SHBG 61 histologic subtype 61 EphB4 61 hypermethylated 61 liver histology 61 LPS induced 61 androgen receptor AR 61 lung metastasis 61 Adjuvant chemotherapy 61 FLT3 ITD 61 HER2 positive tumors 61 hepatocellular carcinomas 61 PKCi 61 EGFR mutant 61 MnSOD 61 Prognostic factors 61 rs# [004] 61 molecular subtypes 61 lupus anticoagulant 61 TNFa 61 scintigraphic 61 CEACAM1 61 TMPRSS2 ERG fusion 61 inhibin 61 NPM1 mutation 61 dehydroepiandrosterone sulfate 61 xenograft models 61 prostate epithelial cells 61 ESR1 61 E#F# 61 invasive carcinoma 61 PECAM 1 61 CD8 + 61 IGFBP2 61 neoadjuvant chemotherapy 61 MDM2 61 prognostic marker 61 seronegative 61 HER2 positivity 61 HBeAg negative 61 CDK4 61 alanine aminotransferase ALT 61 baseline LDH 61 TPMT 61 ADPKD 61 #ß 61 mutant allele 61 glucuronide 61 p# MAPK 61 ELISpot 61 CLL cells 61 TT genotype 61 skeletal metastases 61 CD#b 61 chloride secretion 61 recurrent glioblastoma multiforme 61 K#R [002] 61 eosinophil count 61 lactate dehydrogenase LDH 61 seminomas 61 MGUS 61 thyroid stimulating hormone TSH 61 IGF IR 61 KRAS oncogene 61 intact parathyroid hormone 61 RhoA 61 leukemia AML 61 NKX#.# 61 HLA A2 61 ductal lobular 61 chromosomal aberrations 61 ductal carcinomas 61 Recurrence Score 61 estrone 61 HOMA IR 61 BRCA1 mutation 61 taxane therapy 61 MLH1 61 PSADT 61 methylation patterns 61 SUVmax 61 leiomyoma 61 Cathepsin B 61 ErbB receptors 61 ADAMTS# 61 Foxp3 61 inhibin B 61 APOE genotype 61 PC3 cells 61 diabetes mellitus DM 61 colorectal gastric 61 BRCA gene mutation 61 CIN3 61 TGF b 61 serum thyroglobulin 61 CD# + [001] 61 histologic 61 metastatic lymph nodes 61 retinoic acid receptor 61 paricalcitol 61 K ras gene 61 CCR7 61 diagnostic biomarker 61 neoplasm 61 ALB # 61 inotropic 61 c Src 61 alkaline phosphatase ALP 61 tumor xenografts 61 breast cancer metastasis 61 Lp PLA 2 61 MEK1 61 adrenocortical 61 normal karyotype 61 histologically 61 PON1 61 BALB c mice 61 HOXB# 61 Subgroup analysis 61 beta subunit 61 adenoma 61 e antigen HBeAg 61 HER2 HER3 61 monocyte chemoattractant protein 60 BRCA2 carriers 60 neoplastic cells 60 ErbB2 60 mutational status 60 tumor necrosis 60 SOX9 60 K RAS 60 Rab5 60 IFN α 60 SLC#A# [002] 60 biochemical recurrence 60 60 bladder carcinoma 60 affective psychosis 60 ERK signaling 60 Prostate specific antigen 60 glutamic acid decarboxylase 60 HER2 HER2 60 μg ml 60 HLA B# 60 LNCaP cells 60 D dimer 60 effector memory 60 MGd 60 hypermethylation 60 mesothelin 60 UGT#A# * 60 Leukemias 60 univariate analysis 60 pg ml 60 autoantibodies 60 Cytotoxic T 60 chlamydial infection 60 IL 1β 60 EGFR mutation status 60 HIF 1a 60 grade cervical intraepithelial 60 HuR 60 squamous intraepithelial lesions 60 ventricular tachyarrhythmia 60 micrometastases 60 plasmacytoid dendritic cells 60 hCG beta 60 BRCA deficient 60 multivariable analysis 60 E selectin 60 thyroid carcinoma 60 perineural invasion 60 malignant prostate 60 #β estradiol 60 serum concentrations 60 premalignant lesions 60 extracapsular extension 60 metachronous 60 p#NTR 60 DNA methylation patterns 60 serum PSA 60 HER2 positive 60 cytologically 60 oligodendroglioma 60 induced apoptosis 60 cellularity 60 castration resistant prostate cancer 60 malignant lesions 60 IDH1 mutation 60 liver metastases 60 recurrent ovarian 60 N cadherin 60 NNRTI resistance 60 TGF β 60 miRNA expression 60 Papillary 60 bronchoalveolar lavage 60 EGFr 60 MAPK pathway 60 EGFR gene 60 erythropoiesis 60 selectively inhibited 60 PTEN protein 60 hamartomas 60 heterodimers 60 haematopoietic 60 CDH1 60 downregulated 60 SLN biopsy 60 Response Evaluation Criteria 60 sFlt 1 60 activating mutations 60 mutant p# 60 MMP9 60 clade B 60 cardiac troponin 60 NRTI resistance 60 xenografts 60 pancreatic endocrine 60 transgene expression 60 protein tyrosine phosphatase 60 CDKN2A 60 clusterin 60 transduced 60 axillary node 60 Treg cell 60 AhR 60 CanAg 60 TEL AML1 60 STAT3 activation 60 NPM1 mutations 60 androgenic 60 Selective Inhibitor 60 C#BL/#J 60 Bcl xL 60 selective modulator 60 VKORC1 60 Figure 2C 60 inhibitory effects 60 neuropilin 60 nonalcoholic steatohepatitis NASH 60 peritoneal carcinomatosis 60 intima media thickness 60 FGFR2 60 microglial 60 NAbs 60 proapoptotic 60 lobular carcinomas 60 Inhibin B 60 HCV antibody 60 telomere lengths 60 MGMT gene 60 nonmetastatic 60 PCA3 scores 60 COX2 60 glycosylated 60 TRAIL R2 60 TGFß 60 ectopic expression 60 COL#A# 60 lymphocytic 60 Wwox 60 prognostic markers 60 monocyte 60 xenograft tumors 60 relapsed ovarian cancer 60 mediated immunity 60 nodal metastases 60 somatostatin receptor 60 invasive lobular carcinoma 60 HER2 positive metastatic breast 60 germline mutations 60 SNP rs# [002] 60 tNOX 60 Akt signaling 60 mosaicism 60 castration resistant 60 LRP6 60 cardiac troponin T 60 hypothalamic pituitary 60 genotypic resistance 60 IgG4 60 BRCA mutation 60 apolipoproteins 60 PDE#A 60 Apolipoprotein E 60 5 HTTLPR 60 platelet reactivity 60 Tubulin 60 Jhdm2a 60 EGFR tyrosine kinase inhibitor 60 Hcy 60 bFGF 60 TGF β1 60 glutamyl 60 qRT PCR 60 deacetylation 60 1 diabetes T1D 60 VCAM 1 60 catechol O methyltransferase 60 chemoresistant 60 survivin expression 59 HbF 59 catenin 59 p# antigen 59 vWF 59 pancreatic lung 59 HLA DR2 59 Fas ligand 59 GNAQ 59 HBeAg positive 59 HIF 1alpha 59 serum HBV DNA 59 osteosarcomas 59 multivariate regression analysis 59 TCF#L# 59 prognostic factors 59 HER2 gene 59 mammographically 59 activating mutation 59 hemoglobin Hb 59 IgG antibody 59 APOE e4 59 IL 1beta 59 beta1 integrin 59 genetic polymorphisms 59 Leydig cells 59 Sgk1 59 metastatic malignant 59 BCL2 59 elevated triglyceride levels 59 MSMB 59 aminotransferases 59 variant alleles 59 nutlin 3a 59 KRAS mutation status 59 ADVEXIN efficacy 59 HG PIN 59 heterozygotes 59 HLA B 59 autoimmune thyroid 59 VE cadherin 59 oral squamous cell 59 p# mutations 59 pulmonary metastases 59 Upregulation 59 lymphocyte proliferation 59 oncoprotein 59 tumor xenograft models 59 arachidonic acid AA 59 invasive lobular 59 Squamous 59 CLA supplementation 59 proteolytic processing 59 endoxifen 59 cervical lesions 59 TTR gene 59 liver metastasis 59 bronchoalveolar lavage BAL 59 transactivation 59 BCR ABL 59 leukaemias 59 colorectal adenoma 59 bronchial epithelial cells 59 adjuvant cisplatin 59 neutralizing antibody responses 59 cervical carcinoma 59 Factor Receptor 59 EGF receptors 59 GLI1 59 PITX2 59 C#BL/#J mice 59 trastuzumab Herceptin ® 59 micronuclei 59 adrenalectomy 59 adjuvant radiotherapy 59 PDGFR 59 SGPT 59 DNMT1 59 homodimers 59 chemosensitivity 59 transgenic mice expressing 59 CYP#D# 59 metaplasia 59 lymphoid cells 59 bleomycin 59 LRP5 59 penetrance 59 thymic 59 locoregional 59 erythropoietic 59 tHcy 59 HLA DRB1 * 59 cathepsin B 59 flavopiridol 59 NMDAR 59 plasma leptin 59 colon carcinoma 59 inhibitory receptor 59 Flt3 59 III EGFRvIII 59 myeloproliferative diseases 59 cervical lymph nodes 59 KRAS gene 59 osteoblast 59 somatostatin receptors 59 regulated kinase ERK 59 pmol L 59 gemcitabine carboplatin 59 hyperintensity 59 antigen PSA levels 59 mammographic density 59 factor HGF 59 c KIT 59 CXCL5 59 IGF 1R 59 serum albumin 59 CD4 + CD8 + 59 PON1 gene 59 TNFR1 59 Gleevec resistant 59 paragangliomas 59 oncogenic transformation 59 EGF receptor 59 NGAL 59 EBV infection 59 echocardiographic parameters 59 constitutively expressed 59 metastatic neuroendocrine tumors 59 lymphocyte 59 GATA3 59 hypogonadal 59 gastric carcinomas 59 thyroid stimulating hormone 59 rs# [003] 59 metastatic lesions 59 Histologic 59 AT1R 59 NF kB pathway 59 Fc gamma receptor 59 HGPIN 59 carcinomas 59 FUS1 59 GSTM1 59 SIRT2 59 pleomorphic 59 Tumor Necrosis Factor 59 SMAD4 59 perilipin 59 metastatic HER 59 NAT2 59 CaP 59 bronchoalveolar lavage fluid 59 clinicopathologic 59 FasL 59 vascular endothelial 59 IL #R 59 HCV replicon 59 pegylated liposomal doxorubicin 59 antibody mediated 59 RT PCR assay 59 ^ sup #m 59 EGFR mutations 59 malignant transformation 59 carcinoid 59 miR #a [001] 59 neuroblastoma tumors 59 ALDH 59 eosinophilia 59 #F FDG PET 59 inverse agonist 59 small lymphocytic lymphoma 59 colorectal liver metastases 59 adipogenic 59 carcinoid tumors 59 KLF4 59 Overexpression 59 airway hyper responsiveness 59 CCR5 delta# 59 axillary lymph node 59 specific antigen PSA 59 CDK inhibitor 59 ductal cancer 59 K + ATPase 59 pAkt 59 tumors GIST 59 renal fibrosis 59 MR spectroscopy 59 PC# cells 59 NQO1 59 methylenetetrahydrofolate reductase 59 prognostically 59 serum PTH 59 papillary thyroid carcinoma 59 serum estradiol 59 oligodendrogliomas 59 onset diabetes mellitus 59 proto oncogene 59 Heterozygous 59 ABL1 59 ductal adenocarcinoma 59 testicular germ cell 59 FGFR3 59 induces apoptosis 59 HDAC2 59 BRCA mutations 59 colorectal tumors 59 mouse xenograft models 59 HLA DR 59 HLA DQ2 59 lymphopenia 59 mitogen activated protein kinase 59 pro angiogenic 59 whose tumors overexpress 59 histopathological 59 IFN beta 59 heterozygous 59 PCNSL 59 BCR ABL mutations 59 supratentorial 59 K#N 59 p#Kip# 59 antiangiogenic therapy 59 transfected cells 59 EGFP 59 prostate tumor 59 histone acetylation 59 Smad3 59 TRAIL R1 59 monocyte chemotactic protein 59 annexin V 59 VEGF induced 59 preoperative chemotherapy 59 phosphoprotein 59 lesional 59 KIF6 gene 59 follicle stimulating hormone FSH 59 EGFR receptor 59 papillary RCC 59 p# deficient 59 eIF4E 59 antiandrogens 59 osteoblastic 59 cyclin D1 59 mammary cells 59 metastatic prostate 59 MYCN 59 adrenal cortex 59 Immunohistochemical 59 prognostic indicators 59 PITX2 methylation 59 heparanase 59 alveolar epithelial cells 59 promoter hypermethylation 59 mCRC patients 59 androgen independent 59 metastatic pancreatic 59 adrenal function 59 IgA deficiency 59 plasma lipid 59 lipoxygenase 59 ErbB 59 phosphatidylinositol 59 tumor antigen 59 nitrotyrosine 59 alanine aminotransferase 59 kidney allograft 59 serum cortisol 59 cells transfected 59 cystatin C 59 APOC3 59 BRCA2 mutation carriers 59 hematopoietic cancers 59 urothelial bladder cancer 59 triiodothyronine 59 reticulocytes 59 cathepsins 59 MSH2 59 RhD negative 59 BRCA2 mutation 59 BRCA2 mutations 58 receptor inhibitor 58 differentially expressed genes 58 potent inducer 58 Hurthle cell 58 p#INK#a 58 nondiabetic patients 58 histopathologic 58 DRB1 * 58 H#K#me# 58 melanocyte stimulating hormone 58 airway hyperresponsiveness 58 BRCA1 mutations 58 hematological parameters 58 hCG Beta 58 apolipoprotein A1 58 TGFBR1 * 6A 58 oncoproteins 58 myeloid cells 58 serum HCV RNA 58 endometrial carcinoma 58 opioid receptor 58 receptor blocker 58 proteoglycan 58 thymidine kinase 58 autocrine 58 #.#ng/ml 58 Caveolin 1 58 renal cysts 58 epididymal 58 response pCR 58 HIV RNA 58 anti inflammatory cytokine 58 alkylating agents 58 OPRM1 gene 58 PDGF receptor 58 poly ADP ribose polymerase 58 recurrent ovarian cancer 58 muscle actin 58 BRAF mutations 58 CD# + [002] 58 nNOS 58 EGFR 58 gene rearrangements 58 clonogenic 58 BCL#A 58 PTEN gene 58 T2DM 58 c MET 58 imatinib resistance 58 airway responsiveness 58 lipid abnormalities 58 anaplastic lymphoma kinase 58 imatinib resistant 58 CYT# potent vascular disrupting 58 PI3K Akt 58 metabolic parameters 58 subtype 58 gefitinib Iressa 58 virulence genes 58 PKC inhibitor 58 caveolin 58 Sipuleucel T 58 E. faecalis 58 IgM 58 neurite outgrowth 58 FGFR1 58 alkylating agent 58 metabolizing enzyme 58 SOD2 gene 58 K ras mutation 58 cytologic 58 SHBG levels 58 taxane chemotherapy 58 GBM tumors 58 ptau 58 radiosensitivity 58 hepatic fibrosis 58 SSc 58 thymoma 58 transferrin saturation 58 PCA3 58 papillary renal cell carcinoma 58 steroidogenesis 58 transgenic rats 58 tissue transglutaminase 58 JAK2 58 HDAC6 58 sequence homology 58 EGFR inhibitors 58 T1a 58 breast endometrial 58 acute lymphoblastic leukemia Ph 58 specific antigen 58 serine threonine 58 ductal breast cancer 58 cytopathic 58 selective inhibition 58 demonstrated antitumor activity 58 p# mitogen activated 58 #F FDG 58 mitogen activated protein 58 IV bisphosphonates 58 downregulating 58 aromatase 58 IFNg 58 Genetic variation 58 Pgp 58 panobinostat 58 predictive biomarker 58 ALDH2 58 VEGF receptor 58 MAP kinase 58 TAp# 58 radiotherapy RT 58 bcl 2 58 cytokine signaling 58 myelofibrosis polycythemia vera 58 #beta 58 adiponectin concentrations 58 thymosin 58 advanced adenoma 58 gastrointestinal stromal tumors GISTs 58 protein excretion 58 imatinib therapy 58 mesenteric 58 E cadherin expression 58 polyadenylation 58 S#A# [002] 58 lymphomas leukemias 58 Epidermal Growth Factor Receptor 58 isomerase 58 immunoreactive 58 hydrolase